http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 06 Mar 2026 12:51:35 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Truist+Securities+Reiterates+Buy+Rating+on+Caribou+Biosciences+Inc.+%28CRBU%29+following+Q4+results/26124128.html <p>Truist Securities analyst Asthika Goonewardene reiterated a Buy rating and $7.00 price target on Caribou Biosciences Inc. (NASDAQ: CRBU)</p><p>The analyst commented, "Caribou reported 4Q25 results, closing the year with $143M in cash and equivalents. Management continues to work with the FDA on the design of a pivotal trial for vispa-cel in 2L LBCL. The company also expects to present longer follow-up data from the Phase 1 ANTLER study in 2026. CB-011 remains in enrollment for the dose-expansion cohort of the CaMMouflauge trial, with initial dose-expansion data and additional follow-up from the dose-escalation anticipated in 2026. We reiterate our Buy rating http://www.streetinsider.com/Analyst+Comments/Truist+Securities+Reiterates+Buy+Rating+on+Caribou+Biosciences+Inc.+%28CRBU%29+following+Q4+results/26124128.html Fri, 06 Mar 2026 12:51:35 -0500 CRBU http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Caribou+Biosciences%2C+++++++++++++++++/26120289.html si-local-file:///var/storage/secattach/20260305/26120289.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Caribou+Biosciences%2C+++++++++++++++++/26120289.html Thu, 05 Mar 2026 17:12:00 -0500 CRBU O.51128759 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Caribou+Biosciences%2C+++++++++++++++++/26120289.html si-local-file:///var/storage/secattach/20260305/26120289.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Caribou+Biosciences%2C+++++++++++++++++/26120289.html Thu, 05 Mar 2026 17:12:00 -0500 CRBU O.51128759 http://www.streetinsider.com/Earnings/Caribou+Biosciences%2C+Inc.+%28CRBU%29+Tops+Q4+EPS+by+4c/26120187.html <p>Caribou Biosciences, Inc. (NASDAQ: CRBU) reported Q4 EPS of ($0.28), $0.04 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $3.94 million versus the consensus estimate of $2.17 million.</p><p>For earnings history and earnings-related data on Caribou Biosciences, Inc. (CRBU) <a href="http://www.streetinsider.com/ec_earnings.php?q=CRBU">click here</a>.</p> http://www.streetinsider.com/Earnings/Caribou+Biosciences%2C+Inc.+%28CRBU%29+Tops+Q4+EPS+by+4c/26120187.html Thu, 05 Mar 2026 17:04:52 -0500 CRBU http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Caribou+Biosciences%2C++++++For%3A+Dec+31/26118952.html si-local-file:///var/storage/secattach/20260305/26118952.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Caribou+Biosciences%2C++++++For%3A+Dec+31/26118952.html Thu, 05 Mar 2026 16:10:00 -0500 CRBU O.51128759 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Caribou+Biosciences%2C++++++For%3A+Dec+31/26118952.html si-local-file:///var/storage/secattach/20260305/26118952.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Caribou+Biosciences%2C++++++For%3A+Dec+31/26118952.html Thu, 05 Mar 2026 16:10:00 -0500 CRBU O.51128759 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Caribou+Biosciences%2C++++++For%3A+Mar+05/26118902.html si-local-file:///var/storage/secattach/20260305/26118902.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Caribou+Biosciences%2C++++++For%3A+Mar+05/26118902.html Thu, 05 Mar 2026 16:08:00 -0500 CRBU O.51128759 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Caribou+Biosciences%2C++++++For%3A+Mar+05/26118902.html si-local-file:///var/storage/secattach/20260305/26118902.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Caribou+Biosciences%2C++++++For%3A+Mar+05/26118902.html Thu, 05 Mar 2026 16:08:00 -0500 CRBU O.51128759 http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26118789.html <p>BERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OuLyMfRMYUPtCWHFn-RBquVcinkI-BXL4_pMZZUn1u4GdciEfk13WlE0ZQqi6-as68w3eUiQzQEJdwKjg-1Lv_mgFhv3BtciarJRoJKTgT8=" rel="nofollow" target="_blank">Caribou Biosciences</a>, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for fourth quarter and full year 2025 and provided an overview of recent corporate highlights.</p> <p>“2025 was a year of strong execution for Caribou as we advance two potentially best-in-class allogeneic CAR-T cell therapy programs,” said Rachel Haurwitz, PhD, Caribou’s president and CEO. “The vispa-cel ANTLER phase 1 data in second-line LBCL patients demonstrated efficacy and durability on par with autologous CAR-T therapy and solidified our confidence that this http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26118789.html Thu, 05 Mar 2026 16:05:00 -0500 A.50213784 CRBU O.08407916 O.51128759 http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26118789.html <p>BERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OuLyMfRMYUPtCWHFn-RBquVcinkI-BXL4_pMZZUn1u4GdciEfk13WlE0ZQqi6-as68w3eUiQzQEJdwKjg-1Lv_mgFhv3BtciarJRoJKTgT8=" rel="nofollow" target="_blank">Caribou Biosciences</a>, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for fourth quarter and full year 2025 and provided an overview of recent corporate highlights.</p> <p>“2025 was a year of strong execution for Caribou as we advance two potentially best-in-class allogeneic CAR-T cell therapy programs,” said Rachel Haurwitz, PhD, Caribou’s president and CEO. “The vispa-cel ANTLER phase 1 data in second-line LBCL patients demonstrated efficacy and durability on par with autologous CAR-T therapy and solidified our confidence that this http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26118789.html Thu, 05 Mar 2026 16:05:00 -0500 A.50213784 CRBU O.08407916 O.51128759 http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26118789.html <p>BERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OuLyMfRMYUPtCWHFn-RBquVcinkI-BXL4_pMZZUn1u4GdciEfk13WlE0ZQqi6-as68w3eUiQzQEJdwKjg-1Lv_mgFhv3BtciarJRoJKTgT8=" rel="nofollow" target="_blank">Caribou Biosciences</a>, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for fourth quarter and full year 2025 and provided an overview of recent corporate highlights.</p> <p>“2025 was a year of strong execution for Caribou as we advance two potentially best-in-class allogeneic CAR-T cell therapy programs,” said Rachel Haurwitz, PhD, Caribou’s president and CEO. “The vispa-cel ANTLER phase 1 data in second-line LBCL patients demonstrated efficacy and durability on par with autologous CAR-T therapy and solidified our confidence that this http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26118789.html Thu, 05 Mar 2026 16:05:00 -0500 A.50213784 CRBU O.08407916 O.51128759 http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26118789.html <p>BERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OuLyMfRMYUPtCWHFn-RBquVcinkI-BXL4_pMZZUn1u4GdciEfk13WlE0ZQqi6-as68w3eUiQzQEJdwKjg-1Lv_mgFhv3BtciarJRoJKTgT8=" rel="nofollow" target="_blank">Caribou Biosciences</a>, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for fourth quarter and full year 2025 and provided an overview of recent corporate highlights.</p> <p>“2025 was a year of strong execution for Caribou as we advance two potentially best-in-class allogeneic CAR-T cell therapy programs,” said Rachel Haurwitz, PhD, Caribou’s president and CEO. “The vispa-cel ANTLER phase 1 data in second-line LBCL patients demonstrated efficacy and durability on par with autologous CAR-T therapy and solidified our confidence that this http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26118789.html Thu, 05 Mar 2026 16:05:00 -0500 A.50213784 CRBU O.08407916 O.51128759 http://www.streetinsider.com/Globe+Newswire/Caribou+Biosciences+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26118789.html <p>BERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OuLyMfRMYUPtCWHFn-RBquVcinkI-BXL4_pMZZUn1u4GdciEfk13WlE0ZQqi6-as68w3eUiQzQEJdwKjg-1Lv_mgFhv3BtciarJRoJKTgT8=" rel="nofollow" target="_blank">Caribou Biosciences</a>, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for fourth quarter and full year 2025 and provided an overview of recent corporate highlights.</p> <p>“2025 was a year of strong execution for Caribou as we advance two potentially best-in-class allogeneic CAR-T cell therapy programs,” said Rachel Haurwitz, PhD, Caribou’s president and CEO. “The vispa-cel ANTLER phase 1 data in second-line LBCL patients demonstrated efficacy and durability on par with autologous CAR-T therapy and solidified our confidence that this http://www.streetinsider.com/Globe+Newswire/Caribou+Biosciences+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26118789.html Thu, 05 Mar 2026 16:05:00 -0500 A.50213784 CRBU O.08407916 O.51128759 http://www.streetinsider.com/Globe+Newswire/Caribou+Biosciences+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26118789.html <p>BERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OuLyMfRMYUPtCWHFn-RBquVcinkI-BXL4_pMZZUn1u4GdciEfk13WlE0ZQqi6-as68w3eUiQzQEJdwKjg-1Lv_mgFhv3BtciarJRoJKTgT8=" rel="nofollow" target="_blank">Caribou Biosciences</a>, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for fourth quarter and full year 2025 and provided an overview of recent corporate highlights.</p> <p>“2025 was a year of strong execution for Caribou as we advance two potentially best-in-class allogeneic CAR-T cell therapy programs,” said Rachel Haurwitz, PhD, Caribou’s president and CEO. “The vispa-cel ANTLER phase 1 data in second-line LBCL patients demonstrated efficacy and durability on par with autologous CAR-T therapy and solidified our confidence that this http://www.streetinsider.com/Globe+Newswire/Caribou+Biosciences+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26118789.html Thu, 05 Mar 2026 16:05:00 -0500 A.50213784 CRBU O.08407916 O.51128759 http://www.streetinsider.com/Globe+Newswire/Caribou+Biosciences+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26118789.html <p>BERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OuLyMfRMYUPtCWHFn-RBquVcinkI-BXL4_pMZZUn1u4GdciEfk13WlE0ZQqi6-as68w3eUiQzQEJdwKjg-1Lv_mgFhv3BtciarJRoJKTgT8=" rel="nofollow" target="_blank">Caribou Biosciences</a>, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for fourth quarter and full year 2025 and provided an overview of recent corporate highlights.</p> <p>“2025 was a year of strong execution for Caribou as we advance two potentially best-in-class allogeneic CAR-T cell therapy programs,” said Rachel Haurwitz, PhD, Caribou’s president and CEO. “The vispa-cel ANTLER phase 1 data in second-line LBCL patients demonstrated efficacy and durability on par with autologous CAR-T therapy and solidified our confidence that this http://www.streetinsider.com/Globe+Newswire/Caribou+Biosciences+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26118789.html Thu, 05 Mar 2026 16:05:00 -0500 A.50213784 CRBU O.08407916 O.51128759 http://www.streetinsider.com/Globe+Newswire/Caribou+Biosciences+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26118789.html <p>BERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OuLyMfRMYUPtCWHFn-RBquVcinkI-BXL4_pMZZUn1u4GdciEfk13WlE0ZQqi6-as68w3eUiQzQEJdwKjg-1Lv_mgFhv3BtciarJRoJKTgT8=" rel="nofollow" target="_blank">Caribou Biosciences</a>, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for fourth quarter and full year 2025 and provided an overview of recent corporate highlights.</p> <p>“2025 was a year of strong execution for Caribou as we advance two potentially best-in-class allogeneic CAR-T cell therapy programs,” said Rachel Haurwitz, PhD, Caribou’s president and CEO. “The vispa-cel ANTLER phase 1 data in second-line LBCL patients demonstrated efficacy and durability on par with autologous CAR-T therapy and solidified our confidence that this http://www.streetinsider.com/Globe+Newswire/Caribou+Biosciences+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26118789.html Thu, 05 Mar 2026 16:05:00 -0500 A.50213784 CRBU O.08407916 O.51128759 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Caribou+Biosciences%2C++++++For%3A+Feb+25++Filed+by%3A+Kelly+Timothy+P/26081397.html si-local-file:///var/storage/secattach/20260227/26081397.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Caribou+Biosciences%2C++++++For%3A+Feb+25++Filed+by%3A+Kelly+Timothy+P/26081397.html Fri, 27 Feb 2026 16:01:00 -0500 CRBU O.51128759 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Caribou+Biosciences%2C++++++For%3A+Feb+25++Filed+by%3A+Kelly+Timothy+P/26081397.html si-local-file:///var/storage/secattach/20260227/26081397.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Caribou+Biosciences%2C++++++For%3A+Feb+25++Filed+by%3A+Kelly+Timothy+P/26081397.html Fri, 27 Feb 2026 16:01:00 -0500 CRBU O.51128759 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Caribou+Biosciences%2C+++++++++++++++++++Filed+by%3A+Khan+Ruhi+Ahmad/26062462.html si-local-file:///var/storage/secattach/20260225/26062462.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Caribou+Biosciences%2C+++++++++++++++++++Filed+by%3A+Khan+Ruhi+Ahmad/26062462.html Wed, 25 Feb 2026 21:42:00 -0500 CRBU O.51128759 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Caribou+Biosciences%2C+++++++++++++++++++Filed+by%3A+Khan+Ruhi+Ahmad/26062462.html si-local-file:///var/storage/secattach/20260225/26062462.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Caribou+Biosciences%2C+++++++++++++++++++Filed+by%3A+Khan+Ruhi+Ahmad/26062462.html Wed, 25 Feb 2026 21:42:00 -0500 CRBU O.51128759 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Caribou+Biosciences%2C+++++++++++++++++++Filed+by%3A+MCCLUNG+BARBARA+G/26062461.html si-local-file:///var/storage/secattach/20260225/26062461.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Caribou+Biosciences%2C+++++++++++++++++++Filed+by%3A+MCCLUNG+BARBARA+G/26062461.html Wed, 25 Feb 2026 21:41:00 -0500 CRBU O.51128759 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Caribou+Biosciences%2C+++++++++++++++++++Filed+by%3A+MCCLUNG+BARBARA+G/26062461.html si-local-file:///var/storage/secattach/20260225/26062461.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Caribou+Biosciences%2C+++++++++++++++++++Filed+by%3A+MCCLUNG+BARBARA+G/26062461.html Wed, 25 Feb 2026 21:41:00 -0500 CRBU O.51128759 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Caribou+Biosciences%2C+++++++++++++++++++Filed+by%3A+Kelly+Timothy+P/26061659.html si-local-file:///var/storage/secattach/20260225/26061659.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Caribou+Biosciences%2C+++++++++++++++++++Filed+by%3A+Kelly+Timothy+P/26061659.html Wed, 25 Feb 2026 17:16:00 -0500 CRBU O.51128759 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Caribou+Biosciences%2C+++++++++++++++++++Filed+by%3A+Kelly+Timothy+P/26061659.html si-local-file:///var/storage/secattach/20260225/26061659.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Caribou+Biosciences%2C+++++++++++++++++++Filed+by%3A+Kelly+Timothy+P/26061659.html Wed, 25 Feb 2026 17:16:00 -0500 CRBU O.51128759 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Caribou+Biosciences%2C++++++For%3A+Feb+20++Filed+by%3A+Kelly+Timothy+P/26053892.html si-local-file:///var/storage/secattach/20260224/26053892.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Caribou+Biosciences%2C++++++For%3A+Feb+20++Filed+by%3A+Kelly+Timothy+P/26053892.html Tue, 24 Feb 2026 20:55:00 -0500 CRBU O.51128759